Protalix BioTherapeutics (PLX) Current Leases (2019 - 2026)

Protalix BioTherapeutics has reported Current Leases for 8 years, with the latest figure at $1.4 million in Q1 2026.

• For the quarter ending Q1 2026, Current Leases rose 0.56% year-over-year to $1.4 million; the trailing twelve-month figure through Mar 2026 stood at $1.4 million (up 0.56% YoY), and the FY2025 full-year result was $1.4 million, down 7.73% from the prior year.
• Current Leases for Q1 2026 stood at $1.4 million, up from $1.4 million in the prior quarter.
• The five-year high for Current Leases was $1.5 million in Q3 2024, with the low at $1.0 million in Q3 2022.
• Average Current Leases over 5 years is $1.3 million, with a median of $1.4 million recorded in 2025.
• Year-over-year, Current Leases fell 19.03% in 2022 and surged 31.3% in 2023.
• Tracing PLX's Current Leases over 5 years: stood at $1.1 million in 2022, then advanced by 26.03% to $1.4 million in 2023, then increased by 6.46% to $1.5 million in 2024, then fell by 7.73% to $1.4 million in 2025, then rose by 3.54% to $1.4 million in 2026.
• The last three Current Leases figures came in at $1.4 million (Q1 2026), $1.4 million (Q4 2025), and $1.4 million (Q3 2025), per Business Quant data.

Peer Comparison